Suppr超能文献

根据 KDIGO 指南解读不同试剂盒检测透析患者血清 PTH 浓度:参考(正常值)值的重要性。

Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values.

机构信息

Department of Clinical Chemistry, University of Liège, CHU Sart-Tilman, Liège, Belgium.

出版信息

Nephrol Dial Transplant. 2012 May;27(5):1950-6. doi: 10.1093/ndt/gfr535. Epub 2011 Sep 22.

Abstract

BACKGROUND

The recommended target range for serum parathyroid hormone (PTH) in dialysis patients has changed from 150 to 300 pg/mL in the KDOQI guidelines to two to nine times the upper normal limit in the KDIGO ones. Although inclusion/exclusion criteria for the reference population are highly important, they are usually not mentioned in the commercial kits. In this study, we used the same reference population of vitamin D-replete normal subjects to establish reference values for 10 commercial PTH kits. We evaluated whether this may improve the classification of dialysis patients according to the KDIGO compared to the use of reference values proposed by the manufacturers.

METHODS

We measured serum PTH with 10 different kits in 149 haemodialysis patients, and 240 25-OH-vitamin D-replete (>75 nmol/L) individuals with an estimated glomerular filtration rate >60 mL/min/1.73 m(2).

RESULTS

For the 10 kits, our upper normal limit was lower than those of the manufacturers. The difference was, however, variable from one kit to another. The two kits that yielded the lowest and the highest absolute concentrations classified differently 84/149 patients (56.4%) according to the KDOQI and 53/149 (36.2%) according to the KDIGO using the manufacturers' normal values. Using our normal values significantly decreased the discrepancies with 24/149 patients (16.1%) being still classified differently. Taking the measurement uncertainty into consideration, 8% of the patients only remained differently classified by these two kits.

CONCLUSIONS

Using the same vitamin-D-replete population to establish the reference range for 10 commercial PTH kits significantly improved the classification of haemodialysis patients according to the KDIGO target range.

摘要

背景

在 KDOQI 指南中,透析患者血清甲状旁腺激素(PTH)的推荐靶范围已从 150 至 300 pg/mL 更改为 KDIGO 指南中的两倍至九倍于正常上限。尽管参考人群的纳入/排除标准非常重要,但它们通常在商业试剂盒中没有提及。在这项研究中,我们使用相同的维生素 D 充足的正常参考人群来建立 10 种商业 PTH 试剂盒的参考值。我们评估了与使用制造商建议的参考值相比,根据 KDIGO 对透析患者进行分类的情况是否会有所改善。

方法

我们使用 10 种不同的试剂盒在 149 名血液透析患者和 240 名 25-羟维生素 D 充足(>75 nmol/L)估计肾小球滤过率>60 mL/min/1.73 m²的个体中测量血清 PTH。

结果

对于 10 种试剂盒,我们的上限正常范围低于制造商的范围。然而,这种差异在从一种试剂盒到另一种试剂盒时是可变的。两种试剂盒的绝对浓度最低和最高,根据 KDOQI,使用制造商的正常范围,84/149 名患者(56.4%)和 53/149 名患者(36.2%)分类不同。使用我们的正常范围,有 24/149 名患者(16.1%)的差异明显减少,仍被分类不同。考虑到测量不确定度,只有 8%的患者仅由这两种试剂盒分类不同。

结论

使用相同的维生素 D 充足人群来建立 10 种商业 PTH 试剂盒的参考范围,显著改善了根据 KDIGO 靶范围对血液透析患者的分类。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验